X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA CIPLA AJANTA PHARMA/
CIPLA
 
P/E (TTM) x 18.4 39.3 46.7% View Chart
P/BV x 4.3 3.6 119.2% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 AJANTA PHARMA   CIPLA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
CIPLA
Mar-18
AJANTA PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,818663 274.2%   
Low Rs1,106479 230.9%   
Sales per share (Unadj.) Rs239.5189.0 126.7%  
Earnings per share (Unadj.) Rs52.817.6 300.1%  
Cash flow per share (Unadj.) Rs59.534.0 174.9%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs230.0176.7 130.1%  
Shares outstanding (eoy) m88.77805.12 11.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.13.0 202.1%   
Avg P/E ratio x27.732.5 85.3%  
P/CF ratio (eoy) x24.616.8 146.4%  
Price / Book Value ratio x6.43.2 196.8%  
Dividend payout %017.1 0.0%   
Avg Mkt Cap Rs m129,782459,724 28.2%   
No. of employees `0006.823.6 28.8%   
Total wages/salary Rs m3,76526,901 14.0%   
Avg. sales/employee Rs Th3,128.46,446.1 48.5%   
Avg. wages/employee Rs Th554.01,139.4 48.6%   
Avg. net profit/employee Rs Th689.7600.0 114.9%   
INCOME DATA
Net Sales Rs m21,258152,193 14.0%  
Other income Rs m2423,577 6.8%   
Total revenues Rs m21,499155,769 13.8%   
Gross profit Rs m6,58428,264 23.3%  
Depreciation Rs m59613,228 4.5%   
Interest Rs m41,142 0.4%   
Profit before tax Rs m6,22617,470 35.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m1,5392,501 61.5%   
Profit after tax Rs m4,68614,166 33.1%  
Gross profit margin %31.018.6 166.8%  
Effective tax rate %24.714.3 172.7%   
Net profit margin %22.09.3 236.9%  
BALANCE SHEET DATA
Current assets Rs m12,236108,141 11.3%   
Current liabilities Rs m3,46138,322 9.0%   
Net working cap to sales %41.345.9 90.0%  
Current ratio x3.52.8 125.3%  
Inventory Days Days6097 62.1%  
Debtors Days Days8474 113.5%  
Net fixed assets Rs m11,140109,411 10.2%   
Share capital Rs m1771,610 11.0%   
"Free" reserves Rs m20,237140,682 14.4%   
Net worth Rs m20,414142,292 14.3%   
Long term debt Rs m1036,621 0.0%   
Total assets Rs m24,486228,606 10.7%  
Interest coverage x1,519.416.3 9,325.3%   
Debt to equity ratio x00.3 0.2%  
Sales to assets ratio x0.90.7 130.4%   
Return on assets %19.26.7 286.1%  
Return on equity %23.010.0 230.6%  
Return on capital %30.510.0 306.4%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,66751,691 22.6%   
Fx outflow Rs m1,61621,033 7.7%   
Net fx Rs m10,05230,658 32.8%   
CASH FLOW
From Operations Rs m2,85414,628 19.5%  
From Investments Rs m-2,604-8,540 30.5%  
From Financial Activity Rs m-2-3,855 0.1%  
Net Cashflow Rs m2482,431 10.2%  

Share Holding

Indian Promoters % 73.8 16.0 461.3%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 1.6 12.2 12.7%  
FIIs % 7.6 23.7 32.1%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.0 26.2 64.9%  
Shareholders   20,968 161,166 13.0%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   SANOFI INDIA  ABBOTT INDIA  PLETHICO PHARMA  DR. REDDYS LAB  TORRENT PHARMA  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 383 Points Lower; Realty and Auto Stocks Drag(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)

Oct 8, 2018

While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Are These Deep Corrections a Buying Signal?(Chart Of The Day)

Oct 5, 2018

The correction has bought many good companies to reasonable valuations. Go against the wisdom of crowd and Buy.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Oct 17, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS